黑料网

Pancreatic cancer is a formidable disease with a high mortality rate, characterized by its aggressive nature, limited treatment options, and a propensity for metastasis. Within this complex landscape, a subgroup of cells known as pancreatic cancer stem cells (PCSCs) has emerged as a critical player [1, 2]. These cells possess unique characteristics that contribute to disease progression, treatment resistance, and the potential for distant spread. Understanding the implications of cell surface markers, prognosis, resistance mechanisms, metastatic potential, and treatment strategies associated with PCSCs is crucial for advancing our knowledge and improving outcomes for patients battling this devastating cancer [3- 5].

Cell surface markers and identification

PCSCs, analogous to their normal stem cell counterparts, exhibit distinct cell surface markers that set them apart from the bulk of the tumor. Identification and isolation of these markers, such as CD44, CD133, and EpCAM, allow for a deeper understanding of PCSC biology and facilitate their targeting for therapeutic purposes [6 ]. The presence of these markers not only aids in the characterization of PCSCs but also holds potential as prognostic indicators.

Prognostic significance

The presence and abundance of PCSCs within pancreatic tumors have been associated with poorer prognosis. These cells are thought to contribute to tumor initiation, maintenance, and recurrence. Their ability to self-renew and differentiate into various cell types fuels tumor growth, and their survival under adverse conditions contributes to therapeutic resistance. Therefore, identifying PCSCs in patient samples could provide valuable insights into disease progression and guide treatment decisions [7, 8].

Resistance mechanisms

PCSCs are often resistant to conventional chemotherapy and radiation treatments, contributing to the limited success of these approaches. Their inherent plasticity and adaptive capabilities enable them to evade the effects of therapeutic interventions. Understanding the molecular and cellular mechanisms responsible for PCSC resistance is imperative for designing strategies to overcome treatment barriers and improve patient outcomes [8].

Metastatic potential

Metastasis is a defining feature of aggressive cancers, including pancreatic cancer. PCSCs are believed to play a pivotal role in this process, as they possess the ability to disseminate from the primary tumor, survive in the circulation, and establish secondary tumors in distant organs. Targeting PCSCs may hold the key to preventing or mitigating the spread of pancreatic cancer, thereby enhancing the overall efficacy of therapeutic interventions [10, 11].

Treatment strategies

Developing effective treatment strategies for pancreatic cancer remains a significant challenge. Given their central role in disease progression, PCSCs have garnered attention as potential therapeutic targets. Strategies aimed at disrupting PCSC self-renewal pathways, promoting differentiation, and sensitizing these cells to existing treatments is being explored. Additionally, immunotherapeutic approaches that harness the immune system's ability to recognize and eliminate PCSCs are being investigated [12].

Conclusion

The comprehensive analysis of pancreatic cancer stem cells reveals their multifaceted role in tumor progression, metastasis, therapy resistance, and poor prognosis. Understanding the association of these cells with cell surface markers, their impact on clinical outcomes, and their contributions to treatment resistance and metastasis is pivotal for developing effective therapeutic strategies. Targeting pancreatic CSCs offers a promising avenue for improving the currently limited treatment options for pancreatic cancer and potentially transforming the landscape of patient care.

Acknowledgement

None

Conflict of Interest

None

1. de Wilde RF, Besselink MG, van der Tweel I, de Hingh IHJT, van Eijck CHJ, et al. (2012) . Br J Surg 99: 404-410.

, Google Scholar,

2. Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, et al. (2011) . Br J Surg 98: 1455-1462.

, ,

3. Kostalas M, Nageswaran H, Froghi S, Riga A, Kumar R, et al. (2018) Centralisation for resection of the pancreatic head: a comparison of operative factors and early outcomes during the evolving unit and tertiary unit phases at a UK institution. Am J Surg 216: 310-313.

, ,

4. Polonski A, Izbicki JR, Uzunoglu FG (2019) . J Gastrointest Surg 23: 2081-2092.

, ,

5. Han SS, Park SJ, Kim SH (2012) . Pancreas 41: 102-106.

, ,

6. Ravikumar R, Sabin C, Abu Hilal M (2017) . Br J Surg 104: 1539-1548.

, ,

7. Dua MM, Tran TB, Klausner J (2015) . HPB 17: 824-831.

Indexed at, ,

8. Lee DY, Mitchell EL, Jones MA (2010) . J Vasc Surg 51: 662-666.

, ,

9. Mizrak D, Brittan M, Alison M (2008) . J Pathol 214: 3-9.

, ,

10. Li T, Su Y, Mei Y, Leng Q, Leng B (2010) . Lab Invest 90: 234-244.

, ,

11. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG (2008) . Cancer Res 68: 1820-1825.

, ,

12. Huang R, Wang S, Wang N, Zheng Y, Zhou J (2020) . Cell Death Dis 11: 234.

, ,